comparemela.com
Home
Live Updates
GSKs RSV Vaccine, AREXVY, Accepted Under Priority Review in US for the Prevention of RSV Disease in Adults Aged 50-59 at Increased Risk -February 06, 2024 at 07:04 am EST : comparemela.com
GSK's RSV Vaccine, AREXVY, Accepted Under Priority Review in US for the Prevention of RSV Disease in Adults Aged 50-59 at Increased Risk -February 06, 2024 at 07:04 am EST
Application supported by positive results of a phase III trial showing immune response and acceptable tolerability profile in this population
Adults aged 50 and above with underlying medical...
Related Keywords
Canada ,
Brentford ,
Hounslow ,
United Kingdom ,
Japan ,
Middlesex ,
United Kingdom General ,
J Clin Virol ,
Richard Osei Yeboah ,
Saponiqx Inc ,
Centers For Disease ,
Agenus Inc ,
Antigenics Inc ,
Drug Administration ,
Priority Review ,
Respiratory Syncytial Virus Vaccine ,
Priority Review Voucher ,
Biologics License Application ,
Prescription Drug User Fee Act ,
Syncytial Virus Vaccine ,
Safety Information ,
Annual Report ,
West Road ,
Clin Infect ,
Clinical Outcomes ,
Respiratory Syncytial Virus ,
Prospective Multicenter ,
Immune Response ,
Vaccine Against Respiratory Syncytial Virus Given ,
Including Adults ,
Increased Risk ,
Older Adults ,
New Englj Med ,
Disease Control ,
Chronic Medical Conditions ,
Markets ,
comparemela.com © 2020. All Rights Reserved.